Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082433 · ClinicalTrials.gov registry record · Phase 3
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
A Phase 3 study of Breast Cancer and Cancer, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,221
- Enrollment target
- 20
- Study locations
NCT00082433 is a Phase 3 study of Breast Cancer and Cancer that has completed, run by R-Pharm. The registered enrollment target is 1,221 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT00082433, a Phase 3 study of Breast Cancer and Cancer, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,221 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Ixabepilone + Capecitabine
Study Locations (20)
New York
- Local Institution - Latham
- Local Institution - Mineola
- Local Institution - New York
- Local Institution - The Bronx
California
- Local Institution - Beverly Hills
- Local Institution - Corona
Arizona
- Local Institution - Tucson
Connecticut
- Local Institution - Hartford
Florida
- Local Institution - Plantation
Idaho
- Local Institution - Boise
Illinois
- Local Institution - Evanston
Iowa
- Local Institution - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,221 participants |
| Start Date | 2003-11 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082433
The ClinicalTrials.gov registry entry for NCT00082433 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,221 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (56% lower). The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT00082433 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00082433 about?
NCT00082433 is a clinical study titled "Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer". The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. T...
What is the current status of trial NCT00082433?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,221 participants. The study started on 2003-11. Estimated completion is 2008-03.
What conditions does trial NCT00082433 study?
This clinical trial studies the following conditions: Breast Cancer, Cancer.
What interventions are being tested in trial NCT00082433?
The interventions under investigation include: Capecitabine (DRUG), Ixabepilone + Capecitabine (DRUG).
Who is sponsoring clinical trial NCT00082433?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00082433 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.